Profile and investment
| Fund type | Open Ended Investment Company |
|---|---|
| Investment style (stocks) | Market Cap: Large Investment Style: Growth |
| Morningstar category | Tactical Allocation |
| Launch date | 26 Feb 2010 |
| Price currency | USD |
| Domicile | United States |
| Symbol | ABRUX |
| Manager & start date | Daniel Lew 01 May 2023 |
| Pricing frequency | Daily |
|---|---|
| Total net assets | 4.47m USD As of Apr 30 2024 |
| Share class size | 1.71m USD As of Apr 30 2024 |
| Net expense ratio | 3.37% |
| Front end load | 2.50% |
| Deferred load | -- |
| Maximum Redemption Fee | 1.00% |
| Min. initial investment | 1,000.00 USD |
| Min. additional investment | 50.00 USD |
| Initial IRA | 1,000.00 USD |
| Additional IRA | 50.00 USD |
| Available for sale | United States |
More ▼
Top 5 holdings
| Top 5 holdings as a per cent of portfolio | |||
|---|---|---|---|
| 29.93% | 29.87% | 0.00% | 29.87% |
| Category average | % Net assets | % Short | % Long |
| Company | 1 year change | Portfolio weight | Long allocation |
|---|---|---|---|
| TG Therapeutics Inc TGTX:NAQ | -53.57% | 6.28% | |
| Monte Rosa Therapeutics Inc GLUE:NSQ | +15.07% | 6.10% | |
| Gritstone bio Inc GRTS:NSQ | -61.18% | 6.09% | |
| Nu Holdings Ltd NU:NYQ | +125.48% | 6.04% | |
| Eli Lilly and Co LLY:NYQ | +70.45% | 5.36% | |
| Per cent of portfolio in top 5 holdings: 29.87% |
Asset type
| US stock | 80.45% |
| Non-US stock | 12.51% |
| Cash | 7.04% |
| US bond | 0.00% |
| Non-US bond | 0.00% |
| Other | 0.00% |
Top 5 sectors
| Healthcare | 29.94% |
| Technology | 26.19% |
| Consumer Cyclical | 14.94% |
| Communication Services | 5.27% |
| Basic Materials | 4.93% |
| Other | 11.68% |
Top 5 regions
| United States | 80.45% |
| Europe - ex Euro | 5.74% |
| Latin America | 4.02% |
| Emerging Asia | 2.75% |
Sector and region weightings are calculated using only long position holdings of the portfolio.
